Speaking to 4BC, Dr. Scholss explained what they are hoping to achieve from the clinical trial:
“What we’re really hoping for is to be able to see that the medicinal cannabis aids and assists the standard treatments in reducing tumours, in reducing regrowth, and increasing the person’s end of life quality.”
“There’s over 1,000 a year diagnosed with GBM in Australia alone. The survival rate is usually less than a year.. some people can be gone within 6 months.
So, something that we can find which helps reduce the tumour growth, as well as decreasing the risk of regrowth, will make a big difference to so many people’s lives.”
Research on the potential medicinal applications of cannabinoids has increased in Australia following a rescheduling of cannabis in 2017, similar to the recent reclassification in the UK.
Previously, research into cannabis, in both the UK and Australia, could only be conducted if it was investigating the side-effects of the plant when used as a recreational drug.
With more research, we are gaining more and more evidence that cannabis has great potential to be used alongside current treatments, such as chemotherapy and radiotherapy.
There is already a bounty of anecdotal and preliminary evidence that cannabinoids can help treat cancers, in particular helping to improve the quality of life in terminal cancer patients.
Hopefully, the research conducted by Schloss and Teo will help improve the survival rates of brain cancer patients.